FC
17 hours ago
$NRXP conversation
It's very likely that NRx will be responsible for worldwide commercialization operations in covid play. $RLFTF will sit back and enjoy its 50% split and focus its Aviptadil resources on Sarcoidosis. It's a speculation on my part. But one can't help thinking along this direction with the recent manufacturing and trial development especially in the EU region.
~ FC, Y@h00 RLFTF finance conversations
REPLIES:
Chris
Chris
2 hours ago
@FC a request for invoices and budget breakdown are not big asks…especially if you've signed a CA that voids you of all financial risk…not providing something as basic as invoices or budgets is a MASSIVE red flag, every company on the plant would have stopped funding
Petersen
Petersen
3 hours ago
@FC No whining here fella. I just can’t believe how deluded you are.
FC
FC
12 hours ago
@Petersen at the most critical point of the project, Relief started to play invoice/audit tactics because Ram bailed on the risk involved. I've shown in multiple posts that NeuroRx's charge was nothing out of ordinary for clinical development. It was actually on the lower end. Also for inhaled, there were no invoice per sei at that time. Just you in or not? NeuroRx had to raised its own funding for that. Inhaled project was delayed for 6 months. I am not sure why weren't you angry if you were really for covid play? Thank God funding is no longer on the critical path. If you are not investing here, you have no contribution to this funding process. What are you whining for?
Petersen
Petersen
12 hours ago
@FC So the absolute rebuttal of your argument “doesn’t matter”. That’s very rational of you.
FC
FC
14 hours ago
@Petersen it doesn't matter anymore. Does NRx look like they need Relief funding now? Relief abandoned covid play at the most critical time by holding funding and not fund the inhaled project. We all suffer from that. Ram gets a second chance now during meditation process to commit or pass. No more wait and see gamit anymore
stockparty
stockparty
15 hours ago
@FC ty for calling out the flush
Petersen
Petersen
15 hours ago
@FC No invoices = No funding
stockparty
stockparty
15 hours ago
It's possible but seemingly unlikely given the progress made thus far. Interesting that stocktwits message board (listed on yahoo ADMP) mentions Zyesami as being a victim of a conspiracy. Given the piggyback clause it's a little harder to believe. One thing is for sure if you are part of the Javitt family you don't have to make your roti by hand anymore.
FC
FC
15 hours ago
@12345 who #$%$ abandoned the covid play at the most critical time?
Alexander
Alexander
15 hours ago
I agree
12345
12345
16 hours ago
@FC don?t forget all the #$%$ off shareholders that will be lingering out there. i would sleep with one eye open
FC
FC
16 hours ago
@Franz Relief doesn't have any operation resources - it signed contracts with two European partners one year ago and we never heard back anything, zero. So we shall see.
Franz
Franz
16 hours ago
You say #$%$ as usual.Go on ROW or EU and you will be well received.Take this lawsuit, go bankrupt, and close this mouth. Or surrender. Your call. Muted.
FC
FC
17 hours ago
The RLF-100 formulation issue runs deep. It looks like it not only has the stability and manufacturability issue, it might also have the potency issue. That's one of main reasons why Ram wasn't fully committed and why he went for AdVita. It would take ages for Relief to set up manufacturing in EU and ROW even if NRx/Nephron IP gets shared. The best arrangement for both is for NRx to handle the operations and they split the profit. Let's see how it plays out come Jan.
